Alisertib
- Generic Name
- Alisertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H20ClFN4O4
- CAS Number
- 1028486-01-2
- Unique Ingredient Identifier
- T66ES73M18
- Background
Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.
- Indication
For the treatment of various forms of cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06369285
- Locations
- 🇺🇸
Alliance Cancer Specialists, Horsham, Pennsylvania, United States
🇪🇸Hospital ClÃnico Universitario de Valencia, València, Spain
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06095505
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, United States
🇺🇸Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04555837
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT04479306
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Collin Blakely
- Target Recruit Count
- 38
- Registration Number
- NCT04085315
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 96
- Registration Number
- NCT02860000
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02812056
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 47
- Registration Number
- NCT02719691
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02700022
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, United States
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT02560025
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.